https://www.selleckchem.com/pr....oducts/nvp-bgt226.ht
zygaena. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.BACKGROUND Chemotherapy-induced peripheral neuropathy (CIPN) is regarded as one of the most common dose-limiting adverse effects of several chemotherapeutic agents, such as platinum derivatives (oxaliplatin and cisplatin), taxanes, vinca alkaloids and bortezomib. CIPN affects more than 60% of patients receiving anticancer therapy and although it is a nonfatal condition, it significantly worsens patients' q